The safety and efficacy of autologous concentrated bone marrow grafting in the treatment of osteonecrosis and non-union - The safety and efficacy of autologous concentrated bone marrow grafting

Department of Orthopaedics Surgery, Faculty of Medicine, University of Tsukuba0 个研究点目标入组 20 人开始时间: 2016年2月9日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•A) a patient who is indicated to change the prescriptions of drugs for osteoporosis or steroid within 3 months (except dose reduction and withdrawal) B) a patient who is not candidates for Teriparatide C) a patient who is diabetes (HbA1C>9%) D) a patient who is arteriosclerosis obliterans E) a patient who is difficult to discontinue Warfarin F) Brinkman index>600 G) a patient who suffered cardiac infarction or brain infarction within 6 months H) a patient who suffered severe heart, liver, or renal dysfunction I) a patient who takes digitalis J) a patient who requires dialysis K) a patient who suffered or suspected malignancy within 5 years L) a patient who suffered hematological malignancy M) a patient who have 1 year to live N) a patient who suffered active infection O) systolic blood pressure < 90 mmHg within 2 weeks) P) Body weight < 40 kg (within 2 weeks) Q) a patient who suffered loss of marrow function (within 2 weeks) R) a patient who does not have voluntary consent S) a patient who is difficult to take informed consent in writing T) others

发起方

Department of Orthopaedics Surgery, Faculty of Medicine, University of Tsukuba